CPIX trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CPIX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 26, 2026, Cumberland Pharmaceuticals Inc. (CPIX) has a Wall Street consensus price target of N/A, based on estimates from 5 covering analysts. The company has a market capitalization of $114M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, CPIX trades at a trailing P/E of -40.1x. Analysts expect EPS to grow +22.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HROWHarrow Health, Inc. | $1.2B | $33.07 | $66.50 | +101.1% | Buy | — | 10 |
 PRPHProPhase Labs, Inc. | $152777 | $0.01 | — | — | — | — | — |
 AYTUAytu BioPharma, Inc. | $18M | $2.28 | — | — | — | — | — |
 CODACoda Octopus Group, Inc. | $122M | $10.78 | $14.00 | +29.9% | Buy | 22.9x | 2 |
 AMRXAmneal Pharmaceuticals, Inc. | $6.3B | $19.77 | $23.20 | +17.3% | Buy | 19.3x | 17 |
 LXRXLexicon Pharmaceuticals, Inc. | $797M | $1.79 | $6.00 | +234.3% | Hold | — | 14 |
 PCRXPacira BioSciences, Inc. | $988M | $25.12 | $29.40 | +17.0% | Hold | 8.7x | 36 |
 PAHCPhibro Animal Health Corporation | $1.4B | $34.45 | $28.00 | -18.7% | Buy | 11.2x | 14 |
 ETONEton Pharmaceuticals, Inc. | $1.6B | $57.68 | $66.67 | +15.6% | Buy | 53.0x | 7 |
 KALAKALA BIO, Inc. | $9M | $0.48 | $18.25 | +3737.3% | Buy | — | 9 |
Quick answers to the most common questions about buying CPIX stock.
The consensus price target for CPIX is $N/A, close to the current price of $7.61 (N/A% implied move). Based on 5 analyst estimates, the stock appears fairly valued near current levels.
CPIX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
CPIX's current price is $7.61 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for CPIX, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
CPIX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CPIX stock forecast based on 5 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
CPIX appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CPIX analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.